MingCeler is a leading biotech enterprise dedicated to next-generation animal model innovation, with a core focus on advancing and commercializing TurboMice™—the industry’s most cutting-edge animal model technology worldwide. Pioneered by Dr. Wu Guangming, this proprietary platform builds on iterative optimizations of tetraploid complementation technology and precision stem cell editing, enabling precise editing of nearly any target gene locus within 3–5 months. MingCeler stands as the world’s first company to translate Tetraploid Complementation Technology (TCT) from laboratory-scale research into large-scale industrial application. TurboMice™ technology addresses long-standing technical bottlenecks plaguing traditional models: lengthy model construction and breeding cycles, as well as low success rates for complex gene-edited mouse models. We provide SPF-grade research-grade mouse models, specialized products, and end-to-end technical support services to a global client base spanning universities, research institutes, hospitals, and biopharmaceutical enterprises focused on life health research and translational medicine.